dermatomycosis

(redirected from Dermatomycoses)
Also found in: Dictionary, Thesaurus, Encyclopedia.

dermatomycosis

 [der″mah-to-mi-ko´sis]
a superficial fungal infection of the skin or of its appendages.

der·ma·to·my·co·sis

(der'mă-tō-mī-kō'sis),
Fungus infection of the skin caused by dermatophytes, yeasts, and other fungi. Compare: dermatophytosis.

dermatomycosis

/der·ma·to·my·co·sis/ (der″mah-to-mi-ko´sis) a superficial fungal infection of the skin or its appendages.

dermatomycosis

[dur′mətō′mīkō′sis]
Etymology: Gk, derma + mykes, fungus, osis, condition
a superficial fungal infection of the skin, characteristically found on parts that are moist and protected by clothing, such as the groin or feet. It is caused by a dermatophyte. See also dermatophytosis. dermatomycotic, adj.

dermatomycosis

A fungal skin infection

der·ma·to·my·co·sis

(dĕr'mă-tō-mī-kō'sis)
Fungus infection of the skin caused by dermatophytes, yeasts, and other fungi.
Compare: dermatophytosis

dermatophytosis

inflammation of skin, nails and hair follicles due to dermatophyte infection, causing erythema, itching, papular vesiculation, interdigital and heel fissures and skin scaling; superficial infections are common in adults, especially those with dyshidrosis, living in community, using communal sports or bathing facilities, diabetics or those on long-term antibiotic or immunosuppressive therapies (see onychomycosis; tinea pedis; Table 1)
Table 1: Treatment of fungal infections of skin and nails
Infection siteAgent
Antimycotic agent (for the treatment of dermatophytosis)
SkinTopical allylamine (e.g. 1% terbinafine cream for 7 days)
Topical imidazoles (e.g. 2% miconazole or 1% clotrimazole for 28 days)
Topical 0.25% amorolfine
Topical 1% econazole
Topical griseofulvin spray (400 μg puff daily for 14 days)
Topical 1% sulconazole
Topical tea tree (manuka) oil
Topical undecenoate (20% zinc undecenoate + 5% undecenoic acid)
Topical Whitfield's ointment (6% benzoic acid + 3% salicylic acid)
Other topicals include: weak iodine solution 2.5%; potassium permanganate paint 1%; salicylate acid cream or alcoholic solution 3-5%; benzoic acid (Whitfield's) ointment; sodium polymetaphosphate dusting powder
Systemic terbinafine (250 mg daily for 2 weeks)
Systemic itraconazole (100 mg daily for 15 days)
Systemic griseofulvin (500 mg daily )
NailTopical amorolfine 0.25% lacquer as an adjunct to systemic treatment
Topical borotannic acid complex acid; Phytex paint (1.46% salicylic acid + 4.89% tannic acid + 3.12% boric acid)
Topical 28% tioconazole lacquer
Topical undecenoate lacquer; Monphytol paint (5% methyl undecenoate + 0.7% propyl undecenoate + 3% salicylic acid + 25% methyl salicylate + 5% propyl salicylate + 3% chlorambucil)
Other topicals: strong iodine 10% solution
Systemic terbinafine (250 mg daily for 12-16 weeks)
Systemic itraconazole (400 mg for 1 week in a month, repeated overall 3 or 4 times)
Anticandidal agent (for the treatment of candidiasis)
SkinTopical antimycotic creams (1% clotrimazole; 1% econazole; 2% miconazole)
Topical nystatin (100 000 units ± 1% tolnaftate)
Antipityriasis versicolor agent (for the treatment of pityriasis versicolor)
SkinTopical 2% ketoconazole
Topical 2.5% selenium sulphide
Topical antimycotic agents (1% clotrimazole; 1% econazole; 2% miconazole; 1% sulconazole; 1% terbinafine)
Systemic fluconazole/itraconazole/ketoconazole/miconazole/voriconazole

dermatomycosis

a fungal infection of the skin or of its appendages by a fungus other than the dermatophytes, Microsporum, Trichophyton or Epidermophyton.
References in periodicals archive ?
The report reviews pipeline therapeutics for Dermatomycoses by companies and universities/research institutes based on information derived from company and industry-specific sources
The report reviews key players involved Dermatomycoses therapeutics and enlists all their major and minor projects
The report assesses Dermatomycoses therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
5% (gel containing an emulsion oil/water) for the treatment of dermatomycoses with localized lesions.
In all, having any foot dermatomycoses was associated with an odds ratio of 2.
A review of the Dermatomycoses products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of the Dermatomycoses pipeline on the basis of route of administration and molecule type.
Holding of genotypic characteristics of dermatomycetes isolated from patients with humans' and animals' dermatomycoses with sequencing ITS (ITS4/ITS5) and SSU region (NS1/ NS4), RPB1, RPB2 regions DNA clinical isolates is the purpose of this study.
Mass lesions of the skin, caused by Ringworm pathogens: cattle's Trichophyton and Microsporum infected by dermatomycoses are registered among imported beef livestock.
A double-blind study in superficial dermatomycoses.
Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses.